What You Ought to Know:
– RadNet, Inc., a nationwide chief in offering high-quality, cost-effective diagnostic imaging companies and digital well being options, and iCAD, Inc., a world chief in AI-powered breast well being options, introduced that they’ve entered right into a definitive merger settlement.
– Below the settlement, RadNet will purchase iCAD for $103M in an all-stock transaction.
Monetary Particulars
Based mostly on RadNet’s closing worth on Monday, April 14, 2025, the transaction is valued at roughly $103 million, or roughly $3.61 per share of iCAD frequent inventory on a completely diluted foundation. This represents an approximate 98% premium to iCAD stockholders, primarily based on iCAD’s closing inventory worth on Monday, April 14, 2025. In accordance with the phrases of the merger settlement, iCAD stockholders will obtain 0.0677 shares of RadNet frequent inventory for every share of iCAD frequent inventory they maintain on the closing of the merger.
iCAD Background
iCAD is concentrated on offering AI-powered options for earlier and extra correct most cancers detection. Headquartered in Nashua, N.H., iCAD’s ProFound Breast Well being Suite gives AI-powered mammography evaluation for breast most cancers detection, density evaluation, and threat analysis. ProFound is utilized by 1000’s of suppliers in over 50 nations. iCAD estimates that its know-how has been used to learn over 40 million mammograms worldwide prior to now 5 years, with almost 30% being tomosynthesis.
“As we be part of forces with RadNet to create a broad providing of AI-driven options, we’ve got the chance to redefine how breast most cancers and different ailments are detected and handled. Collectively, we’ll work to increase entry to cutting-edge instruments, speed up innovation and advance our product roadmaps, empowering radiologists with extra exact, environment friendly and scalable options that ought to finally enhance affected person care and outcomes. With present and future merchandise in breast most cancers detection, threat analysis, density evaluation and breast arterial calcification, we consider RadNet’s scale, entry to information and medical management will guarantee our present and future merchandise are dropped at market, enhancing radiologist and affected person workflow and medical outcomes,” stated Dana Brown, President and CEO of iCAD.
